DE69530196D1 - Methode zum verhindern der aggregation von proteinen/peptiden bei rehydratation oder auftauen - Google Patents

Methode zum verhindern der aggregation von proteinen/peptiden bei rehydratation oder auftauen

Info

Publication number
DE69530196D1
DE69530196D1 DE69530196T DE69530196T DE69530196D1 DE 69530196 D1 DE69530196 D1 DE 69530196D1 DE 69530196 T DE69530196 T DE 69530196T DE 69530196 T DE69530196 T DE 69530196T DE 69530196 D1 DE69530196 D1 DE 69530196D1
Authority
DE
Germany
Prior art keywords
thawing
aggregation
rehydration
peptides
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69530196T
Other languages
English (en)
Other versions
DE69530196T2 (de
Inventor
Joseph Roser
Camilo Colaco
Jaap Kampinga
Christopher Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quadrant Drug Delivery Ltd
Original Assignee
Elan Drug Delivery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22958303&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69530196(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elan Drug Delivery Ltd filed Critical Elan Drug Delivery Ltd
Application granted granted Critical
Publication of DE69530196D1 publication Critical patent/DE69530196D1/de
Publication of DE69530196T2 publication Critical patent/DE69530196T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69530196T 1994-06-02 1995-06-02 Methode zum verhindern der aggregation von proteinen/peptiden bei rehydratation oder auftauen Revoked DE69530196T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25296794A 1994-06-02 1994-06-02
PCT/GB1995/001277 WO1995033488A1 (en) 1994-06-02 1995-06-02 Method of preventing aggregation of various substances upon rehydration or thawing and compositions obtained thereby

Publications (2)

Publication Number Publication Date
DE69530196D1 true DE69530196D1 (de) 2003-05-08
DE69530196T2 DE69530196T2 (de) 2003-11-20

Family

ID=22958303

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69530196T Revoked DE69530196T2 (de) 1994-06-02 1995-06-02 Methode zum verhindern der aggregation von proteinen/peptiden bei rehydratation oder auftauen

Country Status (10)

Country Link
US (2) US6890512B2 (de)
EP (1) EP0762897B1 (de)
JP (2) JP4142095B2 (de)
CN (1) CN1188171C (de)
AT (1) ATE235919T1 (de)
DE (1) DE69530196T2 (de)
DK (1) DK0762897T3 (de)
ES (1) ES2194911T3 (de)
PT (1) PT762897E (de)
WO (1) WO1995033488A1 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5621094A (en) * 1990-05-14 1997-04-15 Quadrant Holdings Cambridge Limited Method of preserving agarose gel structure during dehydration by adding a non-reducing glycoside of a straight-chain sugar alcohol
US5955448A (en) * 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
WO1995033488A1 (en) * 1994-06-02 1995-12-14 Quadrant Holdings Cambridge Limited Method of preventing aggregation of various substances upon rehydration or thawing and compositions obtained thereby
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
WO1996008979A1 (en) 1994-09-22 1996-03-28 Quadrant Holdings Cambridge Limited Compositions for use in rehydration and nutrition during athletic exercise and methods of making same
US6964771B1 (en) * 1995-06-07 2005-11-15 Elan Drug Delivery Limited Method for stably incorporating substances within dry, foamed glass matrices
BR9609743A (pt) 1995-07-27 1999-03-02 Genentech Inc Formulação reconstituída estável método para a preparação de uma formulação artigo manufaturado e uso da formação
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5762961A (en) * 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
US5958455A (en) * 1996-02-09 1999-09-28 Quadrant Holdings Cambridge Ltd Oral solid dosage forms, methods of making same and compositions thereof
US6632648B1 (en) 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
IL124275A (en) 1997-05-02 2002-03-10 Bio Merieux Vitek Inc A method to produce sequences of nucleic acids
US6558901B1 (en) 1997-05-02 2003-05-06 Biomerieux Vitek Nucleic acid assays
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
DK2193809T3 (en) 1999-02-22 2015-05-26 Univ Connecticut The albumin-free Factor VIII formulation
FR2791895B1 (fr) * 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
MXPA04002446A (es) 2001-09-26 2004-07-23 Baxter Int Preparacion de nanoparticulas de tamano de submicras mediante dispersion y remocion de la fase liquida o solvente.
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
EP1458360B1 (de) 2001-12-19 2011-05-11 Novartis AG Pulmonale verabreichung von aminoglykosiden
CA2478327A1 (en) * 2002-03-20 2003-10-02 Advanced Inhalation Research, Inc. Hgh (human growth hormone) formulations for pulmonary administration
US20050163725A1 (en) * 2002-03-20 2005-07-28 Blizzard Charles D. Method for administration of growth hormone via pulmonary delivery
US7008644B2 (en) * 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
EP1625387A4 (de) * 2003-05-13 2007-08-08 Minerva Biotechnologies Corp Lagerung und verwendung von kolloiden
ATE411797T2 (de) 2003-10-23 2008-11-15 Otsuka Pharma Co Ltd Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren
WO2005095950A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Method and device for evaluation of pharmaceutical compositions
CA2624503A1 (en) 2005-10-04 2007-04-12 Alk-Abello A/S Solid vaccine formulation
WO2008065502A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
DK2829282T3 (en) * 2007-03-22 2018-01-02 Univ Colorado Regents Process for preparing an immunologically active adjuvant-linked dried vaccine composition
WO2008125940A2 (en) * 2007-04-17 2008-10-23 Pfizer Products Inc. Nanoparticles comprising non-crystalline drug
US20100080852A1 (en) * 2007-05-03 2010-04-01 Ronald Arthur Beyerinck Phamaceutical composition comprising nanoparticles and casein
WO2008135855A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
WO2008135828A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
WO2008149192A2 (en) * 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
WO2009009552A2 (en) * 2007-07-09 2009-01-15 Novartis Ag Preserving secondary peptide structure
WO2009010842A2 (en) * 2007-07-13 2009-01-22 Pfizer Products Inc. Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
MY152789A (en) 2007-07-31 2014-11-28 Otsuka Pharma Co Ltd Methods for producing aripiprazole suspension and freeze-dried formulation
US20090081785A1 (en) * 2007-09-24 2009-03-26 Hememics Biotechnologies, Inc. Desiccated Biologics And Methods Of Preparing The Same
US20090090022A1 (en) * 2007-10-09 2009-04-09 Hememics Biotechnologies, Inc. Desiccation Chamber and Methods for Drying Biological Materials
EP2240162A4 (de) * 2007-12-06 2013-10-09 Bend Res Inc Nanoteilchen mit einem nicht-ionisierbaren polymer und einem amin-funktionalisierten methacrylat-copolymer
WO2009073215A1 (en) * 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
JP4563476B2 (ja) 2008-07-09 2010-10-13 パナソニック株式会社 符号化器、復号化器及び符号化方法
WO2010036226A1 (en) * 2008-09-26 2010-04-01 George Nelson Process for treatment of rheumatoid arthritis, tremors/parkinson's disease and multiple sclerosis
MX339060B (es) 2008-11-07 2016-05-09 Baxter Int Formulaciones del factor viii.
US9827205B2 (en) * 2008-12-12 2017-11-28 Mallinckrodt Pharma Ip Trading D.A.C. Dry powder fibrin sealant
TW201105346A (en) * 2009-07-06 2011-02-16 Sanofi Aventis Deutschland Heat-stable and vibration-stable insulin preparations
US9943075B2 (en) 2010-02-17 2018-04-17 Hememics Biotechnologies, Inc. Preservation solutions for biologics and methods related thereto
JP5341059B2 (ja) * 2010-11-09 2013-11-13 株式会社大塚製薬工場 幹細胞懸濁液
CN103429347B (zh) 2010-12-09 2015-09-16 艾博特健康公司 使用抗吸附剂以方便样本混合及分析的装置和方法
AU2012255132B2 (en) 2011-05-17 2017-05-25 Soligenix, Inc. Thermostable vaccine compositions and methods of preparing same
CN104023743B (zh) 2011-10-25 2017-05-03 普罗西纳治疗有限公司 抗体制剂和方法
EP2793939A1 (de) * 2011-12-23 2014-10-29 Novartis AG Stabile zusammensetzungen zur immunisierung gegen staphylococcus aureus
JP5432322B2 (ja) * 2012-05-08 2014-03-05 株式会社大塚製薬工場 トレハロース含有肺塞栓形成予防用哺乳動物細胞懸濁液
JP2015525748A (ja) * 2012-06-25 2015-09-07 エマージェント プロダクト デベロップメント ゲイザーズバーグ インコーポレイテッド 温度に安定なワクチン製剤
US10357559B2 (en) 2013-12-27 2019-07-23 Emergent Product Development Gaithersburg Inc. Temperature stable vaccine formulations
AU2015339886B2 (en) * 2014-09-29 2019-05-09 Cook General Biotechnology Llc Uses of trehalose in cell suspensions
US20170332623A1 (en) * 2016-03-28 2017-11-23 Cook General Biotechnology Llc Viable cell compositions, and methods related to same
CN107373662B (zh) * 2017-07-07 2020-12-22 江西清源汉本生物科技有限公司 速溶金银花提取物及其制备方法
CN107307422B (zh) * 2017-07-07 2018-09-18 许辉良 速溶石斛提取物及其制备方法
CN107373663B (zh) * 2017-07-07 2020-12-25 江西清源汉本生物科技有限公司 速溶菊花提取物及其制备方法
CN111295094A (zh) 2017-10-09 2020-06-16 泰尔茂比司特生物技术有限公司 冻干容器及使用冻干容器的方法
CN111278458A (zh) * 2017-10-25 2020-06-12 默沙东公司 佐剂疫苗
JP2022525742A (ja) 2019-03-14 2022-05-19 テルモ ビーシーティー バイオテクノロジーズ，エルエルシー 凍結乾燥用ローディングトレイ組立体及びシステム

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3557717A (en) 1968-05-17 1971-01-26 Gen Mills Inc Process for making candy floss
US3619294A (en) 1968-07-15 1971-11-09 Penick & Ford Ltd Method of combining crystalline sugar with impregnating agents and products produced thereby
US3632357A (en) 1969-07-29 1972-01-04 Standard Brands Inc Method of producing hard candy
US3655442A (en) 1969-08-27 1972-04-11 California & Hawaiian Sugar Method of making sugar and sugar products
US4127502A (en) 1977-06-10 1978-11-28 Eastman Kodak Company Stabilizers for reconstituted, lyophilized samples
DE2748132A1 (de) 1977-10-27 1979-05-03 Behringwerke Ag Stabilisator fuer polysaccharid
US4158544A (en) 1978-07-17 1979-06-19 Beckman Instruments, Inc. Process for preparing a biological composition for use as a reference control in diagnostic analysis
US4588744A (en) 1978-09-19 1986-05-13 Mchugh John E Method of forming an aqueous solution of 3-3-Bis(p-hydroxyphenyl)-phthalide
US4327076A (en) 1980-11-17 1982-04-27 Life Savers, Inc. Compressed chewable antacid tablet and method for forming same
US4327077A (en) 1981-05-29 1982-04-27 Life Savers, Inc. Compressed chewable antacid tablet and method for forming same
US4457916A (en) 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
US4883762A (en) 1983-06-06 1989-11-28 Ciba Corning Diagnostics Corp. Stabilized isoenzyme control products
US4865871A (en) 1983-08-23 1989-09-12 Board Of Regents The University Of Texas System Method for cryopreparing biological tissue
DE3445010A1 (de) 1984-12-10 1986-06-19 Boehringer Mannheim Gmbh Kontroll- bzw. eichserum fuer die lipid-diagnostik
DE3682047D1 (de) * 1985-07-09 1991-11-21 Quadrant Bioresources Ltd Beschuetzung von proteinen und aehnlichem.
US4806343A (en) * 1986-03-13 1989-02-21 University Of Southwestern Louisiana Cryogenic protectant for proteins
US4762857A (en) 1986-05-30 1988-08-09 E. I. Du Pont De Nemours And Company Trehalose as stabilizer and tableting excipient
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
GB8715238D0 (en) * 1987-06-29 1987-08-05 Quadrant Bioresources Ltd Food process
GB8801338D0 (en) 1988-01-21 1988-02-17 Quadrant Bioresources Ltd Preservation of viruses
CA1331133C (en) 1988-03-01 1994-08-02 Michael Jon Pikal Pharmaceutical growth hormone formulations
US5262296A (en) * 1988-03-30 1993-11-16 Toray Industries, Inc. Freeze-dried composition containing enzyme-labeled anti-human interferon-β antibody and enzyme immunoassay kit containing the composition
US5059518A (en) * 1988-10-20 1991-10-22 Coulter Corporation Stabilized lyophilized mammalian cells and method of making same
US5102788A (en) * 1988-11-21 1992-04-07 Hygeia Sciences, Inc. Immunoassay including lyophilized reactant mixture
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
GB8917470D0 (en) 1989-07-31 1989-09-13 Quadrant Bioresources Ltd Composition and method
EP0542914A4 (en) 1990-08-10 1993-11-18 Analytical Control Systems, Inc. Improved diagnostic and therapeutic compositions
US5200399A (en) 1990-09-14 1993-04-06 Boyce Thompson Institute For Plant Research, Inc. Method of protecting biological materials from destructive reactions in the dry state
US5242792A (en) * 1991-02-25 1993-09-07 The United States Of America As Represented By The Secretary Of The Navy Method for the preservation of red blood cells by lyophilization using glycerol or inositol with disaccharides
US5422384A (en) 1992-11-25 1995-06-06 Battelle Memorial Institute Glass/polymer composites and methods of making
DE69428707T2 (de) 1993-08-20 2002-07-11 Nippon Shinyaku Co Ltd Im magen verbleibende zubereitung, quellender formkörper und herstellungsverfahren
US5902565A (en) * 1993-12-24 1999-05-11 Csl Limited Spray dried vaccine preparation comprising aluminium adsorbed immunogens
WO1995033488A1 (en) 1994-06-02 1995-12-14 Quadrant Holdings Cambridge Limited Method of preventing aggregation of various substances upon rehydration or thawing and compositions obtained thereby
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
DE69628007T2 (de) 1995-06-07 2003-11-27 Elan Drug Delivery Ltd Verfahren zur stabilen einarbeitung von substanzen in trockene geschäumte glasmatrizen und auf diese weise hergestellte zusammensetzungen

Also Published As

Publication number Publication date
US6890512B2 (en) 2005-05-10
EP0762897B1 (de) 2003-04-02
CN1156967A (zh) 1997-08-13
DE69530196T2 (de) 2003-11-20
US20010055583A1 (en) 2001-12-27
WO1995033488A1 (en) 1995-12-14
DK0762897T3 (da) 2003-07-21
US20050163750A1 (en) 2005-07-28
PT762897E (pt) 2003-07-31
EP0762897A1 (de) 1997-03-19
CN1188171C (zh) 2005-02-09
JPH10500990A (ja) 1998-01-27
JP2008179636A (ja) 2008-08-07
ES2194911T3 (es) 2003-12-01
JP4142095B2 (ja) 2008-08-27
ATE235919T1 (de) 2003-04-15

Similar Documents

Publication Publication Date Title
DE69530196T2 (de) Methode zum verhindern der aggregation von proteinen/peptiden bei rehydratation oder auftauen
ATE159429T1 (de) Methode zum überbringen von agenzien an zielzellen
DE69231469T2 (de) Verwendung von gentisinsäure oder gentisylalkohol zur stabilisierung von radio-markierten peptiden und proteinen
ATE132164T1 (de) Verfahren zur steigerung und zur hemmung der wirkung eines insulinähnlichen wachstumfaktors
DK0572688T3 (da) Peptider, med organ-beskyttende aktivitet, fremgangsmåde til deres fremstilling og deres anvendelse ved terapi
MX9203519A (es) Metodo de recombinacion para la produccion de inhibidores de proteasa de serina y secuencias de adn utiles para los mismos.
DE68927379T2 (de) Plättchen blockierende peptide
DK568287D0 (da) Relativt lavmolekylaere peptider og deres anvendelse som renininhibitorer
RU94041224A (ru) Пептиды с органозащитной активностью, фармацевтическая композиция на их основе и их применение в терапии
HUP9900506A2 (hu) Protrombinszármazékok
ATE270305T1 (de) Peptide des antisekretorischen faktors, welches krankhafte permeabilitätsanderungen reguliert
DK0901526T3 (da) Cortistatin: neuropeptider, sammensætninger og metoder
DE68917837T2 (de) Peptid-Verbindungen.
ATE211765T1 (de) Neue familie von proteaseinhibitoren und andere biologisch aktive substanzen
ATE226591T1 (de) Oligopeptide hergeleitet von fragmenten des c- reaktiven proteins
FI891020A (fi) Menetelmä proteaasi-inhibiittoriaktiivisuutta omaavien egliinimutanttien valmistamiseksi
NO941377L (no) Cellesykluskontrollerende preparater og fremgangsmåte for anvendelse av slike
SE9604439D0 (sv) New receptor
HUT37557A (en) Presrving of spice paprika grist
IT8300556V0 (it) Sottopiede e tomaia per calzature di qualsiasi tipo in materiali naturali organici o sintetici, ottenuto mediante procedura di saldatura ad alta frequenza
ATE33718T1 (de) Apparat zum sequentiellen abbau von peptiden und proteinen.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: QUADRANT DRUG DELIVERY LTD., RUDDINGTON, NOTTINGHA

8331 Complete revocation